Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2000

View Archived Issues

Genzyme Molecular Oncology enters into new diagnostic licensing agreements

Compound in cinnamon affects glucose metabolism

Omeprazole infusion reduces recurrent bleeding in peptic ulcer patients

Macrophage-derived chemokine found to inhibit HIV replication in primary macrophages

FDA grants approval for Unithroid as thyroid hormone replacement therapy

Theratechnologies to commence phase II trial of ThGRF1-44 in COPD

CS-866 -- a novel angiotensin II antagonist in the news

Vitamin E may prevent endothelial dysfunction

ETA receptor blockade with LU-135252 assessed in preclinical studies

Neuronal cells safely transplanted in stroke patients

AGE formation inhibitor reduces hypertension and oxidative stress in SHRSP

Morphine tolerance inhibited by metabotropic group II receptor agonists

Inhibition of bacterial metabolism offers new tuberculosis drug target

Soluble guanylyl cyclase activation by YC-1 reduces blood pressure in rats

Naked DNA malaria vaccine phase II clinical trial commences

Oral interferon alfa receives orphan drug status for treatment of oral papillomavirus warts

BioChem Pharma and Adherex establish anticancer agreement

Selenazolidine prodrugs synthesized as potential chemopreventive agents

Novel compound LR-90 shows both hypolipidemic and hypoglycemic activities

Pteridine derivatives reported by K.U. Leuven as treatment for autoimmune disorders

Inhibitors of p38MAP kinase under development at Teikoku Hormone

Cysteine and serine protease inhibitors useful for osteoporosis, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...